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Patients treated with allogeneic hematopoietic stem cell transplantation (HSCT) are presumed to be at high
risk for hospital readmission. The objective of this study was to identify the incidence and associated risk
factors for readmissions in allogeneic HSCT patients and to evaluate the effect of readmissions on overall
survival. In this retrospective review, we included 1141 HSCT patients (503 patients receiving a myeloablative
[MAC] HSCT and 638 a reduced-intensity conditioning [RIC] HSCT). We measured rates of readmission at
30 days after discharge from HSCT and by day þ100 after HSCT. Reasons for readmission, risk factors for
readmission, and effect on overall survival were assessed. In the MAC group, 130 of 459 (28.3%) patients were
readmitted within 30 days of discharge and 195 of 456 (42.8%) patients by day 100. In the RIC group, 105 of
600 (17.5%) patients were readmitted within 30 days of discharge and 185 of 595 (31.1%) patients by day 100.
There were signiﬁcantly more readmissions in the MAC group at both the 30-day (P < .001) and day þ100
time points (P < .001). The most frequent reason for readmission was infection (28.2% in MAC group, 27.3% in
RIC group). The occurrence of infection during the index admission was the only risk factor signiﬁcant in both
groups at both time points in the multivariable regression analysis. Readmission was signiﬁcantly associated
with decreased overall survival in both groups and at both time points. MAC patients are readmitted
signiﬁcantly more than RIC patients. Infection is the most common cause of readmission after HSCT and the
occurrence of infection during the index transplantation admission is a signiﬁcant risk factor for readmission.
Readmission within 30 days of discharge and by day þ100 after transplantation was a signiﬁcant risk factor
for a lower 5-year overall survival rate in both groups.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hospital readmissions shortly after index hospitalization
increases health care costs. Recent studies suggest that
approximately 20% or greater of Medicare patients are
readmitted within 30 days of discharge, with the vast
majority of these readmissions being unplanned [1-3]. Much
of the earlier research on 30-day readmissions in the United
States focused on pneumonia, heart failure, and acute
myocardial infarction, with studies demonstrating marked
heterogeneity in readmission rates across the country [4-7].
There is also evidence that readmission rates vary by race
and site of care [8]. Readmissions are felt to be an indicator of
failure of care transition. They are also costly, with Medi-
care spending an estimated 17 billion dollars annually ondgments on page 515.
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ty for Blood and Marrow Transplantation.readmissions within 30 days of discharge [1]. Likewise,
30-day readmissions have become an important quality
metric in health care and the Affordable Care Act has enacted
the Hospital Readmissions Reduction Program [9]. Although
current measures exclude oncology patients, the program
will likely continue to expand to include these patients in
the future. This potentially has signiﬁcant implications for
oncology, as very little is known about the readmission
proﬁles of cancer patients. Gaining a better understanding of
the risk factors for readmissions among the oncology pop-
ulation has the potential to result in substantial health care
cost savings as well as enhance quality of life for oncology
patients.
Hematopoietic stem cell transplantation (HSCT) read-
mission rates are especially poorly described. Although HSCT
is potentially curative for patients with otherwise incurable
hematologic malignancies, the procedure is associated with
signiﬁcant post-transplantation morbidity and mortality.
HSCT results in defects in innate and adaptive immunity that
increase the risk of opportunistic infections. Moreover, there
is an intrinsic risk of graft-versus-host disease (GVHD) and
relapse. These vulnerabilities increase the risk of readmission
Table 1
Readmission Rates
Conditioning 30-Day Readmission Rate Day þ100
Readmission Rate
MAC 130 of 459 (28.3%) 195 of 456 (42.8%)
RIC 105 of 600 (17.5%) 185 of 595 (31.1%)
P Value <.001 <.001
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vulnerabilities is often affected by the type of conditioning
regimen used. Myeloablative conditioning (MAC) regimens
cause irreversible cytopenias. Nonmyeloablative (NMA)
conditioning regimens cause minimal cytopenias. Reduced-
intensity conditioning (RIC), an approach that has become
more common over the years, features cytopenias of variable
duration.
Although HSCT is a relatively uncommon procedure in
general, a 2009 Agency for Healthcare Research and Quality
report noted that it was among the top 10 procedures with
the greatest increase in hospital costs from 2004 to 2007,
with a growth rate of 84.9% from $694 million to $1.3 billion,
related to both costs and the number of hospitalizations [10].
There has been a signiﬁcant increase in the number of
transplantations performed both domestically and world-
wide over the past several years [11]. Transplantation rates
are expected to continue to increase with anticipated
improvements in transplantation technology and supportive
care practices, in addition to the emergence of new in-
dications and alternative graft sources [12,13]. Given the
high-risk nature of these immunocompromised patients, the
threshold to readmit is relatively lower and many quality
metrics cannot be easily generalized to this population. The
purpose of our study was to identify the incidence of and
reasons for readmission in transplantation patients, as well
as to explore associated risk factors for readmission and the
impact of readmission on overall survival (OS).
METHODS
Patients and Setting
A retrospective review of patients receiving MAC, RIC, or NMA condi-
tioning HSCT at Dana Farber/Brigham and Women’s Hospital between
January 1, 2005 and December 31, 2010 was performed. For the purpose of
this analysis, all patients receiving an NMA conditioning regimen were
analyzed as part of the RIC group. Conditioning regimen intensity was
deﬁned according to Center for International Blood and Marrow Transplant
Research criteria [14]. Medical records of 1141 HSCT patients were reviewed,
with 503 patients receiving a MAC transplant and 638 patients receiving a
RIC transplant. The most common MAC regimen used was cyclophospha-
mide with total body irradiation (88% of patients) and the most common RIC
regimen used was ﬂudarabine/busulfan (89% of patients). Recipients of cord
blood units and patients who previously received an allogeneic transplant
were excluded before the analysis. All patients received their stem cells
while admitted to an inpatient bone marrow transplantation unit. Per
institutional guidelines, the RIC transplantation patients were discharged on
day þ1 to 2, unless complications occurred. The MAC transplantation pa-
tients remained hospitalized until their absolute neutrophil count recovered
above 500 cells/uL for 2 days, they were afebrile, and they were able to
manage independently at home. All patients received discharge medication
teaching from an oncology pharmacist, registered nurse, or oncology-
trained physician assistant and discharge precautions teaching from an
oncology registered nurse. Follow-up appointments were arranged by the
inpatient team for within 5 days of discharge.
Measurements
The 30-day after discharge and the day 100 after transplantation, a key
time point in transplantation, readmission rates were examined. Informa-
tion on hospital readmissions was collected retrospectively from the
physician documentation in the electronic chart, including readmissions
outside of the home institution when available. We analyzed age, gender,
race, ethnicity, marital status, distance traveled, median income for home
zip code, insurance type, primary caregiver, disease type, disease risk index
[15], prior treatment with radiation therapy, prior autologous trans-
plantation (for RIC only), disease status at time of transplantation, donor
type, stem cell product type, use of total body irradiation during condi-
tioning (for MAC only), documented infection during index HSCT admission,
grade II to IV GVHD [16] during index HSCT admission, hepatic veno-
occlusive disease (for MAC only) during index HSCT admission, and length
of stay for index HSCT admission. Myeloid malignancies included acute
myelogenous leukemia, myelodysplastic syndromes, myeloproliferative
neoplasms, and chronic myelogenous leukemia. Lymphoid malignanciesincluded acute lymphoblastic leukemia, biphenotypic leukemia, lym-
phomas, multiple myeloma, and plasma cell leukemia. Other conditions
included aplastic anemia and other benign hematologic disorders. Infections
were deﬁned as any documented bacterial, viral, or fungal infections with
isolation of a speciﬁc microorganism. The only exception was pneumonia,
for which the presence of both clinical and radiologic ﬁndings of pneumonia
was accepted as an infection.
Statistical Analysis
To identify the risk factors for 30-day or day þ100 readmission rates,
patients who died during their index transplantation admission or before
the corresponding time points without readmission were excluded (44 in
MAC group, 38 in RIC group). An additional 2 patients who stayed in the
hospital for more than 100 days during their transplantation admission
were also excluded from the day þ100 readmission analysis. Potential risk
factorswere compared betweenpatients readmitted and those not admitted
using the Fisher’s exact test or the Wilcoxon rank-sum test [17,18]. Factors
with a univariate P value less than or equal to .20 were further evaluated in
the multivariable logistic model. To evaluate the impact of 30-day or
day þ100 readmission on survival, a landmark analysis was performed
among the patients who survived beyond the corresponding time points.
Survival curves were estimated using the Kaplan-Meier method and were
tested between groups using the log-rank test [19,20]. The effect of read-
mission on OS was also evaluated in a Cox regression model after adjusting
for age, donor type, and the disease risk index [21].
Funding Source
This study had no external funding.
RESULTS
In the MAC group, 130 of 459 (28.3%) patients were
readmitted within 30 days of discharge and 195 of 456
(42.8%) patients were readmitted by day 100 after trans-
plantation. In the RIC group, 105 of 600 (17.5%) patients were
readmitted within 30 days of discharge and 185 of 595
(31.1%) patients were readmitted by day 100 after trans-
plantation. As shown in Table 1, there were signiﬁcantly
more readmissions in the MAC group at both the 30-day
(P < .001) and day þ100 time points (P < .001).
Taking into account all readmissions, in both groups the
most frequent reasons for readmission were infection (28.2%
in MAC group, 27.3% in RIC group), fever without a source
(19.2% inMAC group,19.9% in RIC group), and GVHD (18.0% in
MAC group, 15.9% in RIC group). Other less common reasons
included veno-occlusive disease, gastrointestinal diagnoses,
acute kidney injury, and neurologic diagnoses. Of the 34 RIC
patients with an initial readmission reason of fever without a
source at the 30-day readmission time point, 15 of the pa-
tients (44%) were neutropenic at the time of readmission.
Baseline characteristics with univariate analysis of both the
readmitted and the not-readmitted subsets for the MAC and
RIC groups at each readmission time point of interest are
summarized in Tables 2 and 3, respectively, and are further
discussed below. Results of the multivariate logistic regres-
sion model of risk factors for each group and time point are
summarized in Table 4 and are further discussed below.
MAC: 30-Day Readmission Risk Factors
Compared with those in the MAC group who was not
readmitted by 30 days after discharge, the readmitted group
Table 2
MAC Patient Characteristics
Variable Readmitted
by 30 Days
(n ¼ 130)
Not Readmitted
by 30 Days
(n ¼ 329)
P Value Readmitted
by Day þ100
(n ¼ 195)
Not Readmitted
by Day þ100
(n ¼ 261)
P Value
Sociodemographic variables
Age, median (range) 45.5 (18-60) 45 (19-59) .66 45 (18-60) 45 (19-59) .80
Male 62 (48) 181 (55) .18 104 (53) 137 (52) .92
Race
White 125 (96) 321 (98) .49 189 (97) 254 (97) .59
Black 1 (1) 3 (1) 1 (1) 3 (1)
Other 34 (3) 5 (2) 5 (2) 4 (2)
Ethnicity
Non-Hispanic 122 (94) 321 (98) .09 183 (94) 257 (98) .01
Hispanic or Latino 8 (6) 8 (2) 12 (6) 4 (2)
Married 74 (57) 227 (69) .02 118 (61) 182 (70) .05
Lives  60 miles away 65 (50) 137 (42) .12 93 (48) 109 (42) .18
Zip code median income  60K 86 (66) 218 (66) .91 125 (64) 176 (67) .61
Primary insurance
Medicaid 15 (12) 27 (8) .53 23 (12) 18 (7) .18
Medicare 4 (3) 10 (3) 6 (3) 8 (3)
Private 111 (85) 291 (88) 165 (85) 235 (90)
Other 0 (0) 1 (0) 1 (1) 0 (0)
Primary caregiver
Spouse or signiﬁcant other 82 (63) 255 (78) .01 132 (68) 204 (78) .08
Parents 25 (19) 40 (12) 35 (18) 29 (11)
Siblings 8 (6) 17 (5) 12 (6) 12 (5)
Children 2 (2) 7 (2) 3 (2) 6 (2)
Other 13 (10) 10 (3) 13 (7) 10 (4)
Disease variables
Disease
Myeloid 83 (64) 230 (70) .43 122 (63) 189 (72) .03
Lymphoid 45 (35) 94 (29) 71 (36) 67 (26)
Other* 2 (2) 5 (2) 2 (1) 5 (2)
DRI
Low risk or n/a 15 (12) 42 (13) .28 23 (12) 30 (11) .26
Intermediate 74 (57) 155 (47) 99 (51) 128 (49)
High 30 (23) 100 (30) 54 (28) 76 (29)
Very high 7 (5) 10 (3) 11 (6) 5 (2)
Unknown 4 (3) 22 (7) 8 (4) 18 (7)
Prior XRT 7 (5) 21 (6) .83 9 (5) 19 (7) .32
In CR at HSCT 75 (58) 208 (63) .34 115 (59) 166 (64) .38
Transplantation variables
HSCT type .02 .10
MRD 47 (36) 162 (49) 78 (40) 130 (50)
MURD 71 (55) 150 (46) 102 (52) 117 (45)
MMRD/MMURD 12 (9) 17 (6) 15 (8) 14 (6)
Donor, unrelated 80 (62) 165 (50) .03 114 (58) 129 (49) .06
Product
PBSC 119 (92) 304 (92) .85 178 (91) 242 (93) .60
BM or PBSCþBM 11 (8) 25 (8) 17 (9) 19 (7)
TBI-containing prep 117 (90) 304 (92) .45 180 (92) 238 (91) .73
Documented infection during HSCT 79 (61) 125 (38) <.001 112 (57) 91 (35) <.001
GVHD II-IV during HSCT 20 (15) 23 (7) .01 29 (15) 12 (5) <.001
VOD during HSCT 8 (6) 12 (4) .31 12 (6) 7 (3) .10
Length of stay for HSCT, d 27 (21-98) 26 (11-104) .004 27 (20-98) 25 (11-81) .003
Days to ﬁrst readmission 11.5 (1-30) – 40 (17-100) –
DRI indicates disease risk index; XRT, radiation therapy; CR, complete response/remission; MRD, matched related donor; MURD, matched unrelated donor;
MMRD, mismatched related donor; MMURD, mismatched unrelated donor; PBSC, peripheral blood stem cells; BM, bone marrow; TBI, total body irradiation;
VOD, veno-occlusive disease.
Values in brackets correspond to percentage rounded to nearest whole number or range for median values.
* Other includes aplastic anemia and other nonmalignant conditions.
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versus 31%, P ¼ .02), with a caregiver other than a spouse or
signiﬁcant other (37% versus 22%, P ¼ .01), with an unrelated
donor (62% versus 50%, P ¼ .03), with documented infection
during HSCT admission (61% versus 38%, P < .001), and with
acute GVHD during HSCT admission (15% versus 7%, P ¼ .01),
and the readmitted patients had longer initial hospital stays
for the transplantation (median days of stay 27 versus 26,
P ¼ .004). A multivariate logistic regression model suggested
that the signiﬁcant risk factors for readmission by 30 days
after discharge in the MAC group were having a child ornonrelative as a primary caregiver versus a spouse or sig-
niﬁcant other (odds ratio [OR], 3.10; P ¼ .04), the occurrence
of acute GVHD during index transplantation admission (OR,
2.60; P ¼ .007), and the occurrence of an infection during the
index admission (OR, 2.51; P < .001).
MAC: Day þ100 Readmission Risk Factors
Of the 195 MAC patients readmitted by day 100 after
transplantation, 145 had 1 readmission, 39 had 2 read-
missions, 9 had 3 readmissions, and 2 had 4 readmissions
during the study period. Compared with those in the MAC
Table 3
RIC Patient Characteristics
Variable Readmitted
by 30 Days
(n ¼ 105)
Not Readmitted
by 30 Days
(n ¼ 495)
P Value Readmitted
by Day þ100
(n ¼ 185)
Not Readmitted
by Day þ100
(n ¼ 410)
P Value
Sociodemographic variables
Age, median, yr 59 (24-73) 58 (17-74) .02 60 (19-73) 57 (17-74) <.001
Male 68 (65) 300 (61) .44 118 (64) 249 (61) .52
Race .10
White 99 (94) 482 (97) .17 175 (95) 401 (98)
Black 3 (3) 7 (1) 6 (3) 4 (1)
Other 3 (3) 6 (1) 4 (2) 5 (1)
Ethnicity .21
Non-Hispanic 103 (98) 479 (97) .75 182 (98) 395 (96)
Hispanic or Latino 2 (2) 16 (3) 3 (2) 15 (4)
Married 81 (77) 352 (71) .23 139 (75) 293 (71) .37
Lives  60 miles away 46 (44) 221 (45) .83 79 (43) 188 (46) .48
Zip code median income  60K 64 (61) 335 (68) .17 124 (67) 271 (66) .85
Primary insurance .04
Medicaid 11 (10) 32 (6) .12 16 (9) 25 (6)
Medicare 21 (20) 68 (14) 37 (20) 52 (13)
Private 73 (70) 392 (79) 132 (71) 330 (80)
Other 0 (0) 3 (1) 0 (0) 3 (1)
Primary caregiver
Spouse or signiﬁcant other 86 (82) 380 (77) .43 151 (82) 313 (76) .50
Parents 3 (3) 27 (5) 8 (4) 22 (5)
Siblings 3 (3) 30 (6) 7 (4) 26 (6)
Children 7 (7) 30 (6) 13 (7) 22 (5)
Other 6 (6) 28 (6) 6 (3) 27 (7)
Disease variables
Disease .007
Myeloid 55 (52) 216 (44) .002 97 (52) 170 (41)
Lymphoid 39 (37) 243 (49) 73 (39) 208 (51)
>1 Malignancy 9 (9) 11 (2) 10 (5) 10 (2)
Other* 2 (2) 25 (5) 5 (3) 22 (5)
DRI
Low risk or n/a 26 (25) 127 (26) .10 44 (24) 109 (26) .15
Intermediate 37 (35) 234 (47) 75 (41) 193 (47)
High 24 (23) 98 (20) 42 (23) 80 (20)
Very high 5 (5) 10 (2) 7 (4) 6 (1)
Unknown 13 (12) 26 (5) 17 (9) 22 (5)
Prior XRT 18 (17) 72 (15) .55 29 (16) 61 (15) .81
Prior Auto SCT 17 (16) 121 (24) .10 31 (17) 105 (26) .02
In CR at HSCT 30 (29) 210 (42) .004 56 (30) 181 (44) <.001
Transplantation variables
HSCT type .16 .09
MRD 29 (28) 176 (36) 53 (29) 151 (37)
MURD 63 (60) 279 (56) 111 (60) 227 (55)
MMRD/MMURD 13 (12) 40 (8) 21 (11) 32 (8)
Donor, unrelated 76 (72) 316 (63) .11 132 (71) 256 (62) .04
Product .20 .20
PBSC 103 (98) 470 (95) 180 (97) 388 (95)
BM or PBSCþBM 2 (2) 25 (5) 5 (3) 22 (5)
Documented infection during HSCT 26 (25) 29 (6) <.001 36 (19) 19 (5) <.001
GVHD II-IV during HSCT 3 (3) 3 (1) .07 3 (2) 3 (1) .38
Length of stay for HSCT, d 8 (6-49) 8 (6-51) .008 8 (6-49) 8 (6-51) .08
Days to readmission 11 (1-30) – 29 (3-99) –
Values in brackets correspond to percentage rounded to nearest whole number or range for median values.
* Other includes aplastic anemia and other non-malignant conditions.
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plantation, the readmitted group had signiﬁcantly more pa-
tients of Hispanic or Latino ethnicity (6% versus 2%, P ¼ .01),
with a lymphoid malignancy (36% versus 26%, P ¼ .03)
compared with a myeloid malignancy, with documented
infection during HSCT admission (57% versus 35%, P < .001),
and with acute GVHD during HSCT admission (15% versus 5%,
P < .001), and the readmitted patients had longer initial
hospital stays for the transplantation (median days of stay 27
versus 25, P ¼ .003). A multivariate logistic regression model
suggested that the signiﬁcant risk factors for readmission by
day þ100 in the MAC group after transplantation were
having a lymphoid malignancy versus a myeloid malignancy(OR, 1.77; P ¼ .01), the occurrence of acute GVHD during in-
dex HSCT admission (OR, 3.98; P < .001), and the occurrence
of infection during index HSCTadmission (OR, 2.47; P< .001).
RIC: 30-Day Readmission Risk Factors
Compared with those in the RIC group who were not
readmitted by 30 days after discharge, the readmitted group
was older (median age 59 versus 58, P ¼ .02), had signiﬁ-
cantly more patients with myeloid malignancies compared
with lymphoid malignancies (55% versus 44%, P ¼ .002),
signiﬁcantly more patients with active disease at the time of
transplantation (71% versus 58%, P ¼ .004), higher rates of
documented infection during HSCT admission (25% versus
Table 4
Risk Factors for Readmission: Logistic Regression Analysis
Effect OR 95% CI P Value
MAC: Model for 30-day readmission
Gender
Male versus female .70 .47-1.10 .10
Caregiver
Children/other versus spouse/
signiﬁcant other
3.10 1.04-9.00 .04
Parents versus spouse/signiﬁcant other 2.46 .96-6.33 .06
Sibling versus spouse/signiﬁcant other 2.21 .69-7.03 .18
Marital status
Married versus single 1.36 .59-3.12 .47
Distance from DFCI
60 miles versus >60 miles 1.38 .89-2.13 .15
Donor type
MMRD/MMURD versus MRD 1.91 .80-4.54 .14
Donor type
MURD versus MRD 1.49 .94-2.36 .09
Acute GVHD
Present during index HSCT admission
versus not
2.60 1.30-5.19 .007
Infection
Present during index HSCT admission
versus not
2.51 1.62-3.89 <.001
RIC: Model for 30 day readmission
Age
58 versus <58 1.19 .67-2.10 .56
Median income by zip code
>60K versus < or equal to 60K 1.44 .86-2.42 .17
Insurance
Medicaid versus private 2.48 .96-5.85 .06
Medicare and self-pay versus private 1.23 .61-2.46 .57
Disease type
Lymphoid versus myeloid .67 .35-1.30 .24
>1 Malignancy versus myeloid 3.30 1.04-10.50 .04
DRI
Very high risk versus low risk .95 .23-4.00 .95
High risk versus low risk .63 .27-1.46 .28
Intermediate risk versus low risk .62 .31-1.24 .18
Prior auto SCT
Yes versus no .87 .42-1.78 .70
CR at transplantation
Active disease or not 1.99 1.13-3.51 .02
Donor type
MMRD/MMURD versus MRD 1.74 .73-4.15 .21
MURD versus MRD 1.32 .74-2.34 .35
Infection
Present during index HSCT admission
versus not
6.09 3.06-12.14 <.001
MA: Model for day D100 readmission
Ethnicity
Non-Hispanic versus Hispanic or Latino .29 .08-.10 .05
Marital status
Married versus single 1.22 .57-2.60 .61
Caregiver
Children/other versus spouse/
signiﬁcant other
1.64 .57-4.68 .36
Parents versus spouse/signiﬁcant other 2.19 .90-5.29 .08
Siblings versus spouse/signiﬁcant other 1.70 .55-5.25 .36
Insurance
Medicaid versus private 1.35 .64-2.88 .43
Medicare and self-pay versus private .81 .25-2.64 .73
Distance from DFCI
60 miles versus >60 miles 1.16 .77-1.75 .48
Disease type
Lymphoid versus myeloid 1.77 1.15-2.75 .01
Other versus myeloid .61 .10-3.67 .59
Donor type
MMRD/MMURD versus MRD 1.25 .53-2.97 .61
MURD versus MRD 1.34 .88-2.04 .18
Acute GVHD
Present during index HSCT admission
versus not
3.98 1.86-8.51 <.001
VOD
Yes versus no 1.93 .69-5.41 .21
(Continued)
Table 4
(continued)
Effect OR 95% CI P Value
Infection
Present during index HSCT admission
versus not
2.47 1.65-3.71 <.001
RIC: Model for day D100 readmission
Age
58 versus <58 1.47 .92-2.34 .10
Insurance
Medicaid versus private 2.06 .91-4.68 .08
Insurance
Medicare and self-pay versus private 1.41 .81-2.46 .23
Prior auto SCT
Yes versus no .88 .50-1.55 .65
Disease type
Lymphoid versus myeloid .64 .38-1.07 .09
>1 Malignancy versus myeloid 1.59 .54-4.72 .40
DRI
Very high risk versus low risk 1.40 .39-5.04 .61
High risk versus low risk .73 .37-1.43 .36
Intermediate risk versus low risk .84 .49-1.46 .54
CR at transplantation
Active disease or not 2.19 1.41-3.42 <.001
Donor type
MMRD/MMURD versus MRD 1.46 .71-3.00 .30
MURD versus MRD 1.22 .78-1.91 .38
Infection during HSCT
Yes versus no 5.57 2.76-11.25 <.001
CI indicates conﬁdence interval; DFCI, Dana-Farber Cancer Institute.
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plantation (P ¼ .008). A multivariate logistic regression
model suggested that the signiﬁcant risk factors for read-
mission by 30 days after discharge in the RIC group were
having greater than 1 hematologic malignancy versus a
single myeloid malignancy (OR, 3.30; P ¼ .04), having active
disease at the time of transplantation (OR, 1.99; P ¼ .02), and
the occurrence of infection during index HSCT admission
(OR, 6.09; P < .001).
RIC: Day þ100 Readmission Risk Factors
Of the 185 RIC patients readmitted by day 100 after
transplantation, 127 had 1 readmission, 37 had 2 read-
missions, 14 had 3 readmissions, and 7 had 4 readmissions
during the study period. Compared with those in the RIC
group who were not readmitted by 100 days after trans-
plantation, the readmitted group was older (median age 60
versus 57, P < .001), had signiﬁcantly fewer patients with
private insurance (71% versus 80%, P ¼ .04), signiﬁcantly
more patients with a myeloid malignancy (52% versus 41%,
P ¼ .007), signiﬁcantly fewer patients with prior autologous
HSCT (17% versus 26%, P ¼ .02), signiﬁcantly more patients
with active disease at the time of transplantation (70% versus
56%, P < .001), more with an unrelated donor (71% versus
62%, P ¼ .04), and more with documented infection during
HSCT admission (19% versus 5%, P < .001). A multivariate
logistic regression model suggested that the signiﬁcant risk
factors for readmission by day þ100 after transplantation in
the RIC group were having active disease at the time of
transplantation (OR, 2.19; P < .001) and the occurrence of
infection during index HSCT admission (OR, 5.09; P < .001).
Effect of Readmission on OS
In a landmark analysis of patients who survived beyond
the studied time points, the 5-year OS for those readmitted
within 30 days of discharge from the index HSCT in the MAC
Figure 1. Overall survival by readmission within 30 days of discharge.
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readmitted (P ¼ .003) (Figure 1). Similarly, OS in the RIC
group was 26% compared with 50% (P < .001) (Figure 1).
The 5-year OS for those readmitted by day 100 after HSCT
in the MAC group was 48% compared with 60% among pa-
tients not readmitted (P¼ .007) and in the RIC groupwas 26%
compared with 57% (P < .001) (Figure 2). After adjusting for
age, donor type, and the disease risk index [15], a multivar-
iable Cox regression analysis conﬁrmed that readmission by
30 days after discharge was signiﬁcantly associated with
decreased OS, with a hazard ratio (HR) (readmitted versus
not readmitted) of 1.58 in the MAC group (P ¼ .002) and 1.68
in the RIC group (P < .001). Similarly, readmission by
day þ100 after transplantation was signiﬁcantly associated
with decreased survival in theMAC group (HR,1.46; P¼ .009)
and in the RIC group (HR, 2.31; P < .001).
DISCUSSION
In this analysis, patients who received MAC were read-
mitted signiﬁcantly more frequently than patients who
received RIC at 30 days after discharge and at day þ100
after transplantation. Reasons for readmission were similar
among both groups, with infection and fever without a
source being the 2 most common reasons. Among both
groups and both time points, infection during the index
transplantation admission was found to be a signiﬁcant risk
factor for readmission. The occurrence of acute GVHD during
the index transplantation admission was a signiﬁcant pre-
dictor of readmission at both time points in theMAC group in
the univariate analysis and for predicting 30-day read-
mission in the multivariate analysis. Lacking evidence of
active disease at the time of transplantation was protective
against readmission in the RIC group at both time points in
both the univariate and multivariate analysis. Readmissionwithin 30 days of discharge or by day þ100 after trans-
plantation was signiﬁcantly associated with a lower 5-year
OS rate in both the RIC and MAC groups, based on univari-
ate and multivariate analysis.
A study at the Cleveland Clinic looking at 30-day read-
missions among 618 adult patients after myeloablative allo-
geneic HSCT demonstrated a readmission rate of 39% [22].
Although this is higher than our reported rate of 28.3%, the
Cleveland study took place over a 20-year period dating back
to 1990 and the supportive care of transplantation patients
and the stringency of matching criteria have evolved in that
time. Similar to our study, infection and fever with or
without a source were the most common reasons for read-
mission. Our study also conﬁrmed the negative impact on
survival seen in the Cleveland study with MAC patients
readmitted by 30 days after discharge. In a multivariable
analysis, the Cleveland study showed total body irradi-
ationebased preparative regimens and infection during in-
dex admission to both be signiﬁcant predictors of 30-day
readmission for MAC patients. Our study conﬁrmed the sig-
niﬁcance of infection during index admission.
A limitation of the study is the generalizability to patients
treated at other cancer centers, as there is variation in the
management of RIC transplantation patients across different
institutions. The procedure can be performed entirely as
an outpatient and, likewise, the ﬁrst admission after the
procedure would not be considered a readmission at such
centers, though it is essentially equivalent as such admissions
are presumably due to an adverse effect related to trans-
plantation. In other centers, RIC patients may remain in-
patients for the entire process, including conditioning, stem
cell infusion, and recovery of the neutrophil count, if appli-
cable, which would likely result in less readmission as a
function of a longer index length of stay. Some centers,
Figure 2. Overall survival by readmission by day þ100 after HSCT.
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day þ1 to 2 after stem cell infusion. A 30-day readmissions
study based on 91 patients undergoing transplantation with
varying conditioning intensities at West Virginia University
between August 2007 and December 2012 demonstrated a
30-day readmission rate of 38% [23]. The only signiﬁcant risk
factor found was documented infection during the index
hospitalization. A cost analysis showed that 30-day read-
missions signiﬁcantly increased 100-day post-transplantation
hospital charges, supporting its use as a quality measure. At
their center, all patients admitted for RIC transplantation
remain as inpatients until their neutrophils have engrafted.
More research is needed to understand how variations in
the management of RIC transplantations affects readmissions
and cost.
Other limitations of our study include it being a single-
institution, retrospective analysis. However, the high vol-
ume at our center allowed us to limit the study to recent
years, which more accurately reﬂects the current state of
transplantation. Some of the variables studied were likely
limited by small sample size. Additionally, a small number of
readmissions to outside institutions were likely missed
because of insufﬁcient documentation. Lastly, our current
analysis did not include cord blood transplantations. Pre-
liminary data from 144 cord blood transplantations at our
institution over a 10-year period through 2013 suggests
higher readmission rates for both the 30-day and day þ100
time points compared with those reported in this analysis, at
33.6% and 46.7%, respectively [24].
Deﬁning preventable readmissions in the transplantation
population is challenging. The procedure is associated with
signiﬁcant risk of serious and potentially fatal infections as
well as GVHD, resulting in a lower threshold to readmit giventhe high-risk nature of the population. The occurrence of
infection during the index transplantation admission is a
factor that can potentially be used from both a preventative
and predictive standpoint. Stringent infection control mea-
sures, such as adherence to hand hygiene, isolation pre-
cautions, and rigorous line care may help prevent some of
the infections that result in readmissions. If patients are
diagnosed with an infection during their transplantation
admission, additional resources could be devoted to ensuring
a safe discharge plan and close follow-up. The occurrence of
acute GVHD during the index transplantation admission
could be treated similarly. Although the studied socio-
demographic and disease-related factors found to be signif-
icant predictors of readmission are largely not preventable,
they can be used to help further identify higher risk patients
who would beneﬁt from additional resources, such as more
frequent appointments, discharge phone calls, or improved
communication with local physicians to decrease the need
for hospital admission.
The changing landscape of medicine has resulted in a
growing focus on quality of care. Although readmissions are
costly and are felt to represent failure of care transition, itmust
be recognized that quality metrics cannot be uniformly
generalized to all populations. There is an overall paucity of
data on the readmission proﬁles of oncology patients. The
allogeneic transplantation population is a particularly unique
subset of patients within oncology and further research is
needed to better understand this group’s readmission proﬁle.
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